Routine Monitoring of CAR-T-Cells Expansion and Persistence in Patients With Aggressive Large B-Cell Lymphoma by Flow Cytometry: A Single-Center Experience

IF 3.9 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2025-10-07 DOI:10.1002/hon.70139

Alexandra Zduniak, Jérémie Martinet, Emilie Lévêque, Stéphanie Becker, David Tonnelet, Elodie Dos Santos, Claire Leroy, Mustafa Alani, Jean Rouvet, Marine Brousseau, Camille Giverne, Alexis Cuffel, Serge Jacquot, Arnaud Roucheux, Alice Veuiller, Nicolas Lecornu, Misa Eugene Norbert, Olivier Boyer, Hervé Tilly, Fabrice Jardin, Jean-Baptiste Latouche, Vincent Camus

{"title":"Routine Monitoring of CAR-T-Cells Expansion and Persistence in Patients With Aggressive Large B-Cell Lymphoma by Flow Cytometry: A Single-Center Experience","authors":"Alexandra Zduniak, Jérémie Martinet, Emilie Lévêque, Stéphanie Becker, David Tonnelet, Elodie Dos Santos, Claire Leroy, Mustafa Alani, Jean Rouvet, Marine Brousseau, Camille Giverne, Alexis Cuffel, Serge Jacquot, Arnaud Roucheux, Alice Veuiller, Nicolas Lecornu, Misa Eugene Norbert, Olivier Boyer, Hervé Tilly, Fabrice Jardin, Jean-Baptiste Latouche, Vincent Camus","doi":"10.1002/hon.70139","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>This retrospective, single-center study evaluated routine flow cytometry (FC) monitoring of CAR-T-cells in 45 patients with aggressive large B-cell lymphoma (LBCL). CAR-T-cells expansion was assessed from Day 0 to Month 12. Peak expansion occurred on Day 7 after axi-cel (median 39.3% of total lymphocytes; 87 cells/mm<sup>3</sup>) and Day 10 for tisa-cel (median 8.1%; 33.2 cells/mm<sup>3</sup>). Greater CAR-T-cells expansion was associated with immune-related toxicity, with median peak levels reaching 52.8% in patients with grade 2 cytokine release syndrome (CRS) versus 6.6% in those without (<i>p</i> < 0.001) and 60.8% in patients with immune effector cell-associated neurotoxicity syndrome (ICANS) versus 15.3% in those without (<i>p</i> < 0.001). Prolonged cytopenia was observed in 65% of patients and more frequently among those with greater CAR-T-cells expansion. This study highlights FC as a practical tool for monitoring CAR-T-cells dynamics in routine practice, with potential implications for early toxicity risk assessment and personalized supportive care.</p>\n </section>\n </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 6","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70139","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70139","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This retrospective, single-center study evaluated routine flow cytometry (FC) monitoring of CAR-T-cells in 45 patients with aggressive large B-cell lymphoma (LBCL). CAR-T-cells expansion was assessed from Day 0 to Month 12. Peak expansion occurred on Day 7 after axi-cel (median 39.3% of total lymphocytes; 87 cells/mm³) and Day 10 for tisa-cel (median 8.1%; 33.2 cells/mm³). Greater CAR-T-cells expansion was associated with immune-related toxicity, with median peak levels reaching 52.8% in patients with grade 2 cytokine release syndrome (CRS) versus 6.6% in those without (p < 0.001) and 60.8% in patients with immune effector cell-associated neurotoxicity syndrome (ICANS) versus 15.3% in those without (p < 0.001). Prolonged cytopenia was observed in 65% of patients and more frequently among those with greater CAR-T-cells expansion. This study highlights FC as a practical tool for monitoring CAR-T-cells dynamics in routine practice, with potential implications for early toxicity risk assessment and personalized supportive care.

Abstract Image

查看原文本刊更多论文

流式细胞术常规监测侵袭性大b细胞淋巴瘤患者car - t细胞扩增和持续性：单中心经验

这项回顾性的单中心研究评估了45例侵袭性大b细胞淋巴瘤（LBCL）患者的常规流式细胞术（FC）监测car - t细胞。从第0天到第12个月评估car - t细胞扩增。轴细胞扩增高峰出现在第7天（中位数占淋巴细胞总数的39.3%，87个细胞/mm3），组织细胞扩增高峰出现在第10天（中位数为8.1%，33.2个细胞/mm3）。较大的car - t细胞扩增与免疫相关毒性相关，2级细胞因子释放综合征（CRS）患者的中位峰值水平达到52.8%，无CRS患者为6.6% (p < 0.001)；免疫效应细胞相关神经毒性综合征（ICANS）患者的中位峰值水平为60.8%，无CRS患者为15.3% （p < 0.001）。在65%的患者中观察到延长的细胞减少，并且在car - t细胞扩增较大的患者中更为常见。这项研究强调了FC作为常规实践中监测car - t细胞动力学的实用工具，对早期毒性风险评估和个性化支持治疗具有潜在意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.